Shiraz E-Medical Journal

Published by: Kowsar
Crossmark

Vaccine Adjuvants: The Current Necessity of Life

Amit Gupta 1 , * and Sushama R. Chaphalkar 1
Authors Information
1 Vidya Pratishthan’s School of Biotechnology (VSBT), Baramati, District Pune, Maharashtra, India
Article information
  • Shiraz E-Medical Journal: July 01, 2015, 16 (7); e28061
  • Published Online: July 22, 2015
  • Article Type: Review Article
  • Received: February 18, 2015
  • Accepted: June 28, 2015
  • DOI: 10.17795/semj28061

To Cite: Gupta A, Chaphalkar S R. Vaccine Adjuvants: The Current Necessity of Life, Shiraz E-Med J. 2015 ; 16(7):e28061. doi: 10.17795/semj28061.

Abstract
Copyright © 2015, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
References
  • 1. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes. XVII-XXIV. J Pathol Bacteriol. 1926; 29(1): 31-40[DOI]
  • 2. Lewis PA, Loomis D. Allergic Irritability : The Formation of Anti-Sheep Hemolytic Amboceptor in the Normal and Tuberculous Guinea Pig. J Exp Med. 1924; 40(4): 503-15[PubMed]
  • 3. Freund J, Casals J, Hosmer EP. Sensitization and Antibody Formation after Injection of Tubercle Bacilli and Paraffin Oil. Exp Biol Med. 1937; 37(3): 509-13[DOI]
  • 4. Johnson AG, Gaines S, Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med. 1956; 103(2): 225-46[PubMed]
  • 5. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974; 59(4): 1317-25[PubMed]
  • 6. Baker PJ, Hiernaux JR, Fauntleroy MB, Stashak PW, Prescott B, Cantrell JL, et al. Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun. 1988; 56(12): 3064-6[PubMed]
  • 7. Mbawuike IN, Wyde PR, Anderson PM. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine. 1990; 8(4): 347-52[PubMed]
  • 8. Hibberd PL, Rubin RH. Immunization strategies for the immunocompromised host: the need for immunoadjuvants. Ann Intern Med. 1989; 110(12): 955-6[PubMed]
  • 9. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 1989; 121(1): 134-45[PubMed]
  • 10. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol. 1995; 6: 141-228[DOI][PubMed]
  • 11. Abraham E. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine. 1992; 10(7): 461-8[PubMed]
  • 12. Guzman CA, Molinari G, Fountain MW, Rohde M, Timmis KN, Walker MJ. Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect Immun. 1993; 61(2): 573-9[PubMed]
  • 13. Edelman R. Vaccine adjuvants. Rev Infect Dis. 1980; 2(3): 370-83[PubMed]
  • 14. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 2000; 30 Suppl 3-70[DOI][PubMed]
  • 15. Gupta A, Khamkar PR, Chaphalkar SR. Immunomodulatory and anti-inflammatory activity of aqueous extract of leaf, stem and root of Ficus religiosa on human whole blood and peripheral blood mononuclear cells. Int J Med Pharm Res. 2014; 2(4): 732-9
  • 16. Gupta A, Khajuria A, Singh J, Bedi KL, Satti NK, Dutt P, et al. Immunomodulatory activity of biopolymeric fraction RLJ-NE-205 from Picrorhiza kurroa. Int Immunopharmacol. 2006; 6(10): 1543-9[DOI][PubMed]
  • 17. Khajuria A, Gupta A, Suden P, Singh S, Malik F, Singh J, et al. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata. Phytother Res. 2008; 22(3): 340-8[DOI][PubMed]
  • 18. Agarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol. 1999; 67(1): 27-35[PubMed]
  • 19. Gupta A, Chaphalkar SR. Use of flow cytometry to measure the immunostimulatory activity of aqueous extract of Jasminum auriculatum. Int J Current Adv Res. 2015;
  • 20. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B. Studies on the immunomodulatory effects of Ashwagandha. J Ethnopharmacol. 1996; 50(2): 69-76[PubMed]
  • 21. Patwardhan B, Kalbag D, Patki PS, Nagasampagi BA. Search of immunomodulatory agents--A review. Indian Drugs. 1990; 28: 56-63
  • 22. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Experimental Med. 1987; 166(5): 1229-44
  • 23. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996; 17(3): 138-46[PubMed]
  • 24. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991; 12(8): 256-7[DOI][PubMed]
  • 25. Brewer JM, Richmond J, Alexander J. The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies. Clin Exp Immunol. 1994; 97(1): 164-71[PubMed]
  • 26. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol. 1990; 8: 773-93[DOI][PubMed]
  • 27. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr Opin Immunol. 1993; 5(1): 27-34[PubMed]
  • 28. Cambier JC, Pleiman CM, Clark MR. Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol. 1994; 12: 457-86[DOI][PubMed]
  • 29. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today. 1995; 16(1): 2-4[PubMed]
  • 30. Driscoll J. The role of the proteasome in cellular protein degradation. Histol Histopathol. 1994; 9(1): 197-202[PubMed]
  • 31. Abel G, Szollosi J, Chihara G, Fachet J. Effect of lentinan and mannan on phagocytosis of fluorescent latex microbeads by mouse peritoneal macrophages: a flow cytometric study. Int J Immunopharmacol. 1989; 11(6): 615-21[PubMed]
  • 32. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995; 375(6527): 151-5[DOI][PubMed]
  • 33. Ribi HO, Ludwig DS, Mercer KL, Schoolnik GK, Kornberg RD. Three-dimensional structure of cholera toxin penetrating a lipid membrane. Science. 1988; 239(4845): 1272-6[PubMed]
  • 34. Chinnah AD, Baig MA, Tizard IR, Kemp MC. Antigen dependent adjuvant activity of a polydispersed beta-(1,4)-linked acetylated mannan (acemannan). Vaccine. 1992; 10(8): 551-7[DOI][PubMed]
  • 35. Allison AC, Byars NE. Immunological adjuvants and their mode of action. Biotechnology. 1992; 20: 431-49[PubMed]
  • 36. Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminum compounds used as adjuvants in vaccines. Pharm Res. 1990; 7(12): 1282-8[PubMed]
  • 37. Al-Shakhshir RH, Regnier FE, White JL, Hem SL. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 1995; 13(1): 41-4
  • 38. Cvjetanovic B, Uemura K. The Present Status of Field and Laboratory Studies of Typhoid and Paratyphoid Vaccines with Special Reference to Studies Sponsored by World Health Organization. Bull World Health Organ. 1965; 32: 29-36[PubMed]
  • 39. Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol. 1968; 100(5): 1139-40[PubMed]
  • 40. Chedid L. Adjuvants of immunity. Ann Inst Pasteur Immunol. 1985; 136D(3): 283-91[DOI][PubMed]
  • 41. O'Hagan DT, McGee JP, Holmgren J, Mowat AM, Donachie AM. Biodegradable microparticles as controlled release antigen delivery systems. Vaccine . 1993; 11: 149-54
  • 42. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 1995; 6: 229-48[PubMed]
  • 43. Woodard LF. Adjuvant activity of water-insoluble surfactants. Lab Anim Sci. 1989; 39(3): 222-5[PubMed]
  • 44. Bomford R. Immunological adjuvants and Vaccines. NATO ASI Series A: Life Sciences Vol. 179. Proceedinas of a NATO Advanced Study institute on Immunological Aldjuvants and Vaccines, 24 June - 5 July 1988, Cape Sounion Beach, Greece. 1989; : 35-41
  • 45. Matsuhasi T. Proceedings of an Informal Consultation on the World Health Organization Requirements for Diphtheria, Tetanus, Pertussis and Combined Vaccines. 1991; : 55-8
  • 46. Cooper PD. Strategies in Vaccine Design Landes RG Company Austin . 1994;
  • 47. Zollinger WD, Boslego JW. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods. 1981; 46(2): 129-40[PubMed]
  • 48. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine. 2001; 19(31): 4363-72[PubMed]
  • 49. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000; 12(4): 456-63[PubMed]
  • 50. Spack EG, Sorgi FL. Developing non-viral DNA delivery systems for cancer and infectious disease. Drug Discov Today. 2001; 6(4): 186-97[PubMed]
  • 51. Kensil CR. Critical Reviews™ in Therapeutic Drug Carrier Systems. 1996; 13: 1-55
  • 52. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs. 1998; 7(9): 1475-82[DOI][PubMed]
  • 53. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine. 1999; 18(7-8): 597-603[DOI][PubMed]
  • 54. Hancock G. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine. 1995; 13(4): 391-400[DOI]
  • 55. Newman MJ, Wu JY, Gardner BH, Munroe KJ, Leombruno D, Recchia J, et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol. 1992; 148(8): 2357-62[PubMed]
  • 56. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995; 55(13): 2783-8[PubMed]
  • 57. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 1994; 12(14): 1275-80[PubMed]
  • 58. Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1997; 13(14): 1163-77[PubMed]
  • 59. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2): 86-91[DOI][PubMed]
  • 60. Brazeau GA, Fung HL. An in vitro model to evaluate muscle damage following intramuscular injections. Pharm Res. 1989; 6(2): 167-70[PubMed]
  • 61. Khajuria A, Gupta A, Singh S, Malik F, Singh J, Suri KA, et al. RLJ-NE-299A: a new plant based vaccine adjuvant. Vaccine. 2007; 25(14): 2706-15[DOI][PubMed]
  • 62. Khajuria A, Gupta A, Malik F, Singh S, Singh J, Gupta BD, et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine. 2007; 25(23): 4586-94[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments